Johnson & Johnson (J&J) has reported its first-quarter 2025 results, showcasing a 2.4% increase in reported sales to $21.9 billion, with operational growth at 4.2% and adjusted operational growth at 3.3%. The company's net earnings surged by a staggering 237.9% to $10.999 billion, and its earnings per share (EPS) soared to $4.54. When adjusted, the EPS increased to $2.77, marking a 2.2% growth.
The company's free cash flow also saw an uptick, reaching approximately $3.4 billion, reflecting a 19% rise from the previous period.
In terms of regional sales, the U.S. market demonstrated robust performance, with reported and operational growth of 5.9%, while international sales reported a 1.8% decline in reported growth, but a 2.1% increase in operational growth.
Segment-wise, J&J's innovative medicine and medtech sectors both saw positive growth, with reported sales increases of 2.3% and 2.5%, respectively.
The company's guidance for full-year 2025 operational sales has been adjusted upward, now ranging from $91.6 billion to $92.4 billion, representing a 3.3% to 4.3% increase. The adjusted operational EPS is expected to range from $10.50 to $10.70, reflecting a growth of 5.2% to 7.2%.
J&J's first-quarter 2025 was marked by significant new product pipeline progress, including the approval of Tremfya in Crohn’s disease, data for Rybrevant/Lazcluze overall survival in non-small cell lung cancer, and ICOTROKINRA in plaque psoriasis, among other achievements.
These results demonstrate the company's strong performance and strategic advancements, positioning it for continued growth and success in the coming quarters. Following these announcements, the company's shares moved -0.3%, and are now trading at a price of $153.84. If you want to know more, read the company's complete 8-K report here.
